Madrigal Pharmaceuticals Q4 2023 Earnings Report

Madrigal Pharmaceuticals EPS Results

• Actual EPS: -$5.68
• Consensus EPS: -$5.26
• Beat/Miss: Missed by -$0.42
• One Year Ago EPS: -$4.98

Madrigal Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Madrigal Pharmaceuticals Announcement Details

• Quarter: Q4 2023
• Date: 2/28/2024
• Time: Before Market Opens
• Conference Call Date: Wednesday, February 28, 2024
• Conference Call Time: 7:00AM ET

Madrigal Pharmaceuticals (NASDAQ:MDGL) (NASDAQ: MDGL) is a clinical-stage biopharmaceutical company focused on the development of targeted therapies for non-alcoholic steatohepatitis (NASH) and other metabolic liver diseases. The company’s lead product candidate, resmetirom (MGL-3196), is an oral, selective thyroid hormone receptor-β agonist designed to reduce liver fat and improve markers of inflammation and fibrosis in patients with NASH. Madrigal is also exploring additional compounds aimed at treating dyslipidemia and cardiovascular risk factors associated with metabolic liver disease.

Since its founding in 2012 and incorporation in Delaware, Madrigal has pursued a strategy of advancing novel, mechanism-based therapies from early discovery through clinical development. The company’s research programs leverage insights into thyroid hormone receptor biology to address underlying drivers of liver injury. Resmetirom has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration, reflecting the unmet medical need in NASH and the promising clinical data observed to date.

Madrigal Pharmaceuticals maintains its headquarters in Conshohocken, Pennsylvania, and operates a lean, clinical-focused organization that partners with contract research organizations and academic investigators across North America and Europe. The company’s global approach to clinical trials seeks to enroll a diverse patient population, with ongoing Phase 3 studies evaluating resmetirom’s efficacy and safety in reducing liver fat and improving histological outcomes.

Under the leadership of President and Chief Executive Officer James E. Sapirstein, who joined Madrigal in 2021, the company has strengthened its management team to support late-stage development and regulatory interactions. With a seasoned board of directors and scientific advisory board composed of experts in hepatology and endocrinology, Madrigal remains committed to delivering transformative therapies for patients suffering from metabolic liver diseases.